A
Alan Ashworth
Researcher at University of California, San Francisco
Publications - 589
Citations - 82138
Alan Ashworth is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 134, co-authored 578 publications receiving 72089 citations. Previous affiliations of Alan Ashworth include Imperial College London & Papworth Hospital.
Papers
More filters
Journal ArticleDOI
An SRY‐related gene expressed during spermatogenesis in the mouse encodes a sequence‐specific DNA‐binding protein.
TL;DR: SRY, the testis determining gene, encodes a member of a family of DNA binding proteins characterized by an amino acid sequence motif known as the HMG box, and Sry can also bind to this motif, indicating that the Sry family may have overlapping sequence specificities.
Journal ArticleDOI
Xist has properties of the X-chromosome inactivation centre
TL;DR: Xist, introduced onto an autosome, is sufficient by itself for inactivation in cis and that Xist RNA becomes localized close to the autosome into which the gene is integrated, suggesting that elements required for some aspects of chromosome counting are contained within the construct.
Journal ArticleDOI
PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors
Konstantin J. Dedes,Daniel Wetterskog,Ana M. Mendes-Pereira,Rachael Natrajan,Maryou B K Lambros,Felipe C. Geyer,Radost Vatcheva,Kay Savage,Alan Mackay,Christopher J. Lord,Alan Ashworth,Jorge S. Reis-Filho +11 more
TL;DR: The authors demonstrate that endometrial cancer cell lines that lack the tumor suppressor protein PTEN show defects in the repair of DNA damage and are consequently very sensitive to drugs that block poly(ADP) ribose polymerase (PARP), an enzyme critical for DNA repair.
Journal ArticleDOI
Tankyrase-targeted therapeutics: expanding opportunities in the PARP family
TL;DR: The biology oftankyrases and the discovery of tankyrase-specific inhibitors are discussed and the challenges that lie ahead for the clinical development of PARP family inhibitors in general are considered.
Journal ArticleDOI
EGFR amplification and lack of activating mutations in metaplastic breast carcinomas
Jorge S. Reis-Filho,Céline Pinheiro,M B K Lambros,Fernanda Milanezi,Fernanda Milanezi,Silvia Carvalho,Kay Savage,Peter T. Simpson,Chris Jones,Sally Swift,Alan Mackay,Rui Manuel Reis,Jason L. Hornick,Emílio M. Pereira,Fátima Baltazar,Christopher D.M. Fletcher,Alan Ashworth,Sunil R. Lakhani,Fernando Schmitt +18 more
TL;DR: It is indicated that further studies are warranted to explore EGFR tyrosine kinase inhibitors as potential therapeutic agents for metaplastic breast carcinomas harbouring amplification of 7p11.2.